Compare BSET & VANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BSET | VANI |
|---|---|---|
| Founded | 1902 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.9M | 116.4M |
| IPO Year | 1995 | 2014 |
| Metric | BSET | VANI |
|---|---|---|
| Price | $20.86 | $1.36 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.50 |
| AVG Volume (30 Days) | 104.8K | ★ 549.9K |
| Earning Date | 04-01-2026 | 05-14-2026 |
| Dividend Yield | ★ 5.49% | N/A |
| EPS Growth | ★ 163.06 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $456,855,000.00 | $4,000,000.00 |
| Revenue This Year | $1.72 | N/A |
| Revenue Next Year | $3.78 | N/A |
| P/E Ratio | $56.76 | ★ N/A |
| Revenue Growth | ★ 0.96 | N/A |
| 52 Week Low | $13.17 | $0.92 |
| 52 Week High | $21.00 | $1.92 |
| Indicator | BSET | VANI |
|---|---|---|
| Relative Strength Index (RSI) | 76.09 | 57.07 |
| Support Level | $14.29 | $1.17 |
| Resistance Level | N/A | $1.55 |
| Average True Range (ATR) | 1.15 | 0.11 |
| MACD | 0.35 | 0.03 |
| Stochastic Oscillator | 93.45 | 47.11 |
Bassett Furniture Industries Inc is a manufacturer, marketer, and retailer of home furnishings products in the United States. It operates through the following segments: The Wholesale segment focuses on the design, manufacture, sourcing, sale, and distribution of furniture products, the Retail segment which consists of company-owned stores, and the Corporate and others segment. Majority of revenue is from Wholesale sales of furniture and accessories.
Vivani Medical Inc is a clinical stage biopharmaceutical company which develops miniature, ultra long-acting subdermal drug implant candidates utilizing its proprietary NanoPortal technology, which is designed to enable reversible, ultra long-acting, near constant-rate delivery of a broad range of medicines to treat chronic diseases. Vivani uses this platform technology to develop, and potentially commercialize, drug implant candidates, alone or in collaboration with pharmaceutical company partners, to address causes of poor clinical outcomes in the treatment of chronic diseases, including medication non-adherence, drug tolerability and administration challenges faced by certain patients. It operates in two segments the Biopharm Division and Neurostimulation Division.